Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 29 new animal drug applications (NADAs) and 2 abbreviated new animal drug applications (ANADAs) from Intervet, Inc., to Schering-Plough Animal Health Corp.

DATES:

This rule is effective November 25, 2009.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8307, e-mail: david.newkirk@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Intervet, Inc., P.O. Box 318, 29160 Intervet Lane, Millsboro, DE 19966, has informed FDA that it has transferred ownership of, and all rights and interest in, the following 29 approved NADAs and 2 approved ANADAs to Schering-Plough Animal Health Corp., 556 Morris Ave., Summit, NJ 07901: NADA 034-478, 034-621, 045-188, 102-380, 104-494, 111-278, 120-648, 121-473, 128-620, 131-310, 131-675, 132-872, 137-600, 138-612, 139-189, 140-856, 140-897, 140-927, 140-954, 140-992, 141-222, 141-236, 141-258, 141-269, 141-276, 141-278, 141-280, 141-282, 141-286; ANADA 200-134 and 200-239. Accordingly, the agency is amending the regulations in 21 CFR parts 520, 522 (21 CFR part 522), and 558 to reflect the transfer of ownership. In addition, § 522.1081 is being revised to reflect a current format.

Following these changes of sponsorship, Intervet, Inc., is no longer the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for Intervet, Inc.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

and 522

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority
[Amended]
Start Amendment Part

2. In § 510.600, in the table in paragraph (c)(1), remove the entry for “Intervet, Inc.”; and in the table in paragraph (c)(2), remove the entry for “057926”.

End Amendment Part Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

4. In paragraph (b) of § 520.48, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

5. In paragraph (b) of § 520.905a, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

6. In paragraph (b) of § 520.905b, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

7. In paragraph (b) of § 520.905c, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

8. In paragraph (b)(1) of § 520.905d, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

9. In paragraph (b) of § 520.905e, remove “057926” and in its place add “No. 000061”.

End Amendment Part
[Amended]
Start Amendment Part

10. In paragraph (b)(2) of § 520.1010, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

11. In paragraph (b) of § 520.1200, remove “057926” and in its place add “000061”.

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

12. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

13. In paragraph (b)(3) of § 522.246, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

14. In paragraph (b)(4) of § 522.1010, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

15. In paragraph (b) of § 522.1078, remove “Nos. 050604, 057926, and 059130” and in its place add “Nos. 000061, 050604, and 059130”.

End Amendment Part
[Amended]
Start Amendment Part

16. In paragraph (b) of § 522.1079, remove “057926” and in its place add “000061”.

End Amendment Part Start Amendment Part

17. Revise § 522.1081 to read as follows:

End Amendment Part
Chorionic gonadotropin.

(a) Specifications. Each vial contains 5,000, 10,000 or 20,000 USP units of lyophilized powder for constitution with accompanying diluent to a 10-milliliter solution.Start Printed Page 61517

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) Nos. 000402 and 053501 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(B) and (d)(1)(i)(C) of this section.

(2) Nos. 058639 and 063323 for use as in paragraphs (d)(1)(i)(A) and (d)(1)(i)(B) of this section.

(3) No. 000061 for use as in paragraphs (d)(1)(i)(A) and (d)(2) of this section.

(c) Related tolerances. See § 556.304 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Amount. As a single dose. Dosage may be repeated in 14 days if the animal's behavior or examination of the ovaries per rectum indicates retreatment.

(A) 10,000 USP units by intramuscular injection.

(B) 500 to 2,500 USP units by intrafollicular injection.

(C) 2,500 to 5,000 USP units by intravenous injection.

(ii) Indications for use. For parenteral use in cows for treatment of nymphomania (frequent or constant heat) due to cystic ovaries.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Finfish—(i) Amount. 50 to 510 IU per pound of body weight for males, 67 to 1,816 IU per pound of body weight for females, by intramuscular injection. Up to three doses may be administered.

(ii) Indications for use. An aid in improving spawning function in male and female brood finfish.

(iii) Limitations. In fish intended for human consumption, the total dose administered per fish (all injections combined) should not exceed 25,000 IU chorionic gonadotropin. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[Amended]
Start Amendment Part

18. In paragraph (b) of § 522.1160, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

19. In paragraph (a)(2) of § 522.2476, remove “057926” and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

20. In paragraph (b)(2) of § 522.2477, remove “057926” and in its place add “000061”.

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

21. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]
Start Amendment Part

22. In paragraph (b) of § 558.258, remove “057926” and in its place add “000061”; and in the tables in paragraphs (e)(1) through (e)(5), in the “Sponsor” column, remove “057926” where it occurs and in its place add “000061”.

End Amendment Part
[Amended]
Start Amendment Part

23. In paragraph (b) of § 558.665, remove “057926” and in its place add “000061”; and in the table in paragraph (e), in the “Sponsor” column, remove “057926” where it occurs and in its place add “000061”.

End Amendment Part Start Signature

Dated: November 19, 2009.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. E9-28217 Filed 11-24-09; 8:45 am]

BILLING CODE 4160-01-S